IP Library Granted Patent US 7,276,597
Granted Patent B2
US 7,276,597 · App. 10/981,942 · Granted Oct 2, 2007

Compositions and kits for detection of a nucleic acid by sequential amplification

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,276,597
App. No.
10/981,942
Granted
Oct 2, 2007
Kind
B2
Abstract

The invention relates to nucleic acid compositions for use in sequential amplification detection assays which permit the detection of a nucleic acid target in a sample.

Claims (76)

1. A composition comprising:

(i) one or more template nucleic acids, each of which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(ii) a first oligonucleotide that is at least partially complementary to said first region of said template nucleic acid; and

(iii) one or more second oligonucleotides corresponding to said one or more template nucleic acids, each of said second oligonucleotides comprising a 5′ region and a 3′ region, wherein each said 3′ region is at least partially complementary to said second region of said corresponding template nucleic acid and wherein each said 5′ region is at least partially complementary to a region that may be upstream of, downstream of, or comprise said first region of said corresponding template nucleic acid.

2. A composition comprising:

(i) a target nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region,

(ii) a template nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region,

(iii) a first oligonucleotide that is at least partially complementary to said first region of said target nucleic acid, and

(iv) a second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target nucleic acid and wherein said 5′ region is not complementary to said extension region of said target nucleic acid but is at least partially complementary to said first region of said template nucleic acid; and

(v) a third oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said template nucleic acid and said 5′ region is not complementary to said template nucleic acid.

3. A composition comprising:

(i) a target nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region,

(ii) a template nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region

(iii) a first oligonucleotide that is at least partially complementary to said first region of said target nucleic acid, and

(iv) a second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target nucleic acid and wherein said 5′ region is at least partially complementary to a region that may be upstream of, downstream of or comprising said first region of said target nucleic acid and is at least partially complementary to said first region of said template nucleic acid; and

(v) a third oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to the second region of the template nucleic acid and the 5′ region is at least partially complementary to a region that may be upstream of, downstream of or comprising said first region of said template nucleic acid.

4. A composition comprising:

(i) one or more template nucleic acids, which comprise in 3′ to 5′ order a first region, a first extension region, a second region, a second extension region, and a third region;

(ii) an upstream primer that is at least partially complementary to said first region of said template nucleic acid;

(iii) one or more first downstream oligonucleotides corresponding to said one or more template nucleic acids, each said first downstream oligonucleotides comprising a 5′ region and a 3′ region, wherein each said 3′ region is at least partially complementary to said second region of said corresponding template nucleic acid and wherein each said 5′ region is at least partially complementary to a region that may be upstream of, downstream of, or comprise said first region of said corresponding template nucleic acid;

(iv) one or more second downstream oligonucleotides corresponding to said one or more template nucleic acids, each said second downstream oligonucleotide comprising a 5′ region and a 3′ region, wherein each said 3′ region is at least partially complementary to said third region of said corresponding template nucleic acid and wherein said 5′ region is at least partially complementary to a region that may be upstream of, downstream of, or comprise said second region of said corresponding template nucleic acid.

5. A composition comprising:

(i) a target nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region,

(ii) a template nucleic acid, which comprises in 3′ to 5′ order a first region, a first extension region, a second region, a second extension region and a third region,

(iii) a first oligonucleotide that is at least partially complementary to said first region of said target nucleic acid, and

(iv) a second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target nucleic acid and wherein said 5′ region is not complementary to said extension region of said target nucleic acid but is at least partially complementary to said first region of said template nucleic acid; and

(v) a third oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said template nucleic acid, and wherein said 5′ region is not complementary to said first extension region of said template nucleic acid, and

(iv) a fourth oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said third region of said template nucleic acid, and wherein said 3′ region of said third oligonucleotide is not identical in sequence to said 3′ region of said fourth oligonucleotide, and wherein said 5′ region of said fourth oligonucleotide is not complementary to said second extension region of said template nucleic acid.

6. A composition comprising:

(i) a target nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region,

(ii) a template nucleic acid, which comprises in 3′ to 5′ order a first region, a first extension region, a second region, a second extension region and a third region,

(iii) a first oligonucleotide that is at least partially complementary to said first region of said target nucleic acid, and

(iv) a second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target nucleic acid and wherein said 5′ region is at least partially complementary to a region that may be upstream of, downstream of, or comprising said first region of said target nucleic acid and is at least partially complementary to said first region of said template nucleic acid; and

(v) a third oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said template nucleic acid, and wherein said 5′ region is at least partially complementary to a region that may be upstream of downstream of or comprising said first region of said template nucleic acid, and

(vi) a fourth oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said third region of said template nucleic acid, and wherein said 3′ region of said third oligonucleotide is not identical in sequence to said 3′ region of said fourth oligonucleotide, and wherein said 5′ region of said fourth oligonucleotide is at least partially complementary to a region that may be upstream of, downstream of or comprising said second region of said template nucleic acid.

7. The composition of any one of claims 1 to 6 further comprising a cleavage means which permits cleavage of a flap from a nucleic acid duplex structure and wherein said cleavage means lacks polymerase activity.

8. The composition of any one of claims 1 to 6 further comprising a nucleic acid polymerizing activity.

9. The composition of any one of claims 1 to 6 further comprising a cleavage means which permits cleavage of a flap from a nucleic acid duplex structure and which lacks polymerase activity and a nucleic acid polymerizing activity.

10. A kit comprising a composition of any one of claims 1 to 6 and packaging materials therefore.

11. The kit of claim 10 , further comprising a cleavage means which permits cleavage of a flap from a nucleic acid duplex structure and wherein said cleavage means lacks polymerase activity.

12. The kit of claim 10 , further comprising a nucleic acid polymerizing activity.

13. The kit of claim 10 , further comprising a cleavage means which permits cleavage of a flap from a nucleic acid duplex structure and which lacks polymerase activity and a nucleic acid polymerizing activity.

14. A composition comprising:

(i) a target nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(ii) a template nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(iii) a first oligonucleotide that is at least partially complementary to said first region of said target nucleic acid;

(iv) a second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target nucleic acid and wherein said 5′ region is not complementary to said target nucleic acid but is at least partially complementary to said first region of said template nucleic acid; and

(v) a third oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said template nucleic acid and said 5′ region is not complementary to said template nucleic acid.

15. A composition comprising:

(i) a target nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(ii) a template nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(iii) a first oligonucleotide that is at least partially complementary to said first region of said target nucleic acid;

(iv) a second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target nucleic acid and wherein said 5′ region is not complementary to said target nucleic acid but is at least partially complementary to said first region of said template nucleic acid; and

(v) a third oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to the second region of the template nucleic acid and said 5′ region is at least partially complementary to a region that is 3′ of said second region of said template nucleic acid.

16. The composition of claim 14 or 15 , further comprising a cleavage means, wherein said cleavage means lacks polymerase activity.

17. The composition of claim 16 , wherein said cleavage means comprises a 5′ nuclease.

18. The composition of claim 14 or 15 , further comprising a polymerase.

19. The composition of claim 14 or 15 , further comprising a cleavage means and a polymerase.

20. The composition of claim 17 , wherein said 5′ nuclease is a FEN-1 nuclease.

21. The composition of claim 19 , wherein said polymerase and said cleavage means are contained in a single enzyme.

22. The composition of claim 19 , wherein said cleavage means is a FEN-1 nuclease and said polymerase is a Pfu DNA Polymerase.

23. The composition of claim 14 or 15 , wherein the 3′ nucleotide of said second oligonucleotide has a blocking group.

24. The composition of claim 14 or 15 , wherein the 3′ nucleotide of said template nucleic acid has a blocking group.

25. A kit comprising a composition of claim 14 or 15 and packaging materials therefore.

26. The kit of claim 25 , further comprising a cleavage means.

27. The kit of claim 25 , further comprising a nucleic acid polymerase.

28. The kit of claim 25 , further comprising a cleavage means and a nucleic acid polymerase.

29. The composition of claim 8 , wherein said polymerizing activity is a polymerase lacking 5′ to 3′ exonuclease activity.

30. The composition of claim 9 , wherein said polymerizing activity is a polymerase lacking 5′ to 3′ exonuclease activity.

31. The kit of claim 12 or 13 , wherein said polymerizing activity is a polymerase lacking 5′ to 3′ exonuclease activity.

32. The composition of claim 18 , wherein said polymerase lacks 5′ to 3′ exonuclease activity.

33. The composition of claim 19 , wherein said polymerase lacks 5′ to 3′ exonuclease activity.

34. The kit of claim 27 , wherein said nucleic acid polymerase lacks 5′ to 3′ exonuclease activity.

35. The kit of claim 28 , wherein said nucleic acid polymerase lacks 5′ to 3′ exonuclease activity.

36. The kit of claim 26 , wherein said cleavage means lacks polymerase activity.

37. The kit of claim 28 , wherein said cleavage means lacks polymerase activity.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
EIGHTH SUPPLEMENT TO PATENT SECURITY AGREEMENT Recorded Mar 26, 2009
From: CYTYC CORPORATION; HOLOGIC, INC.
To: GOLDMAN SACHS CREDIT PARTNERSL.P.
Reel/Frame 022456/0947 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2008
From: STRATAGENE CALIFORNIA
To: HOLOGIC INC.
Reel/Frame 021976/0268 →